R&D News | pharmaphorum

News

Anthropic launches Claude Science for pharma researchers

Anthropic had made a big life sciences play with the launch of Claude Science, an AI 'workbench' for researchers involved in drug discovery.

News

Digital brain inside human head concept for Vistagen

Despite study bust, Vistagen still hopes to file anxiety dru...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.

News

Drugmakers asked to defend Chinese trials; reports

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

Sanofi eyes extending Nexviazyme into infantile Pompe

Armed with new phase 3 data, Sanofi will try to expand the US label of its Pompe disease drug Nexviazyme to include the severe infantile-onset form.

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

Anthropic launches Claude Science for pharma researchers

Despite study bust, Vistagen still hopes to file anxiety dru...

Drugmakers asked to defend Chinese trials; reports

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Sanofi eyes extending Nexviazyme into infantile Pompe

Ipsen charts $1.75bn course for Kartos acquisition

ESMO26: Lowering toxicity, extending lives, with Syncromune

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks